Evotec earns US$40m in global licence deal with BMS
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its 24m (US$26m) Series A financing to advance the clinical development […]
It is just announced that it will soon be possible to taste farmed meat and seafood in the Netherlands under controlled conditions. The Dutch government, in collaboration with cultured meat […]
A long-awaited draft regulation from the EU Commission’s DG Sante to deregulate the authorisation, risk assessment and labelling of a whole range of new genetically modified organisms (GMOs) has been […]
Dutch venture builder NLC has announced a 20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s […]
Carthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its 37.5m […]
Donaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell […]
French AI-powered radiography diagnostics specialist Gleamer SAS has raises 27m in Series B round to expand its portfolio and accelerate its expansion.